Modified diadenosine tetraphosphates with dual specificity for P2Y1 and P2Y12 are potent antagonists of ADP-induced platelet activation

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 12, 2012, Pages 2573-2580

  Chang, H ^a,b   Yanachkov, I B ^c   Dix, E J ^c   Li, Y F ^a   Barnard, M R ^a,d   Wright, G E ^c   Michelson, A D ^a,d   Frelinger, A L ^a,d  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c GLSYNTHESIS INC   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Diadenosine; Platelet; Receptor

Indexed keywords

ADENOSINE DERIVATIVE; ADENOSINE DIPHOSPHATE; CALCIUM ION; DIADENOSINE TETRAPHOSPHATE; DIADENOSINE TETRAPHOSPHATE DERIVATIVE; PURINERGIC P2Y RECEPTOR AGONIST; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y12 RECEPTOR; UNCLASSIFIED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL SHAPE; CHEMICAL MODIFICATION; CONTROLLED STUDY; CYTOSOL; DRUG POTENCY; DRUG SPECIFICITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STRUCTURE ACTIVITY RELATION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

ADENOSINE DIPHOSPHATE; DINUCLEOSIDE PHOSPHATES; HUMANS; PHOSPHORYLATION; PLATELET ACTIVATION; RECEPTORS, PURINERGIC P2Y1; RECEPTORS, PURINERGIC P2Y12;

EID: 84871067166     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12035     Document Type: Article

References (38)

1. Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE Jr, Green LA, Hochman JS, Jacobs AK, Krumholz HM, Morrison DA, Ornato JP, Pearle DL, Peterson ED, Sloan MA, Whitlow PL, et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009; 120: 2271-306.
2. Cattaneo M. The platelet P2 receptors. In: Michelson AD, ed. Platelets, 2nd edn. San Diego, CA: Elsevier/Academic Press, 2007: 201-20.
3. Jankowski J, Jankowski V, Laufer U, van der Giet M, Henning L, Tepel M, Zidek W, Schluter H. Identification and quantification of diadenosine polyphosphate concentrations in human plasma. Arterioscler Thromb Vasc Biol 2003; 23: 1231-8.
4. Zamecnik PC, Kim B, Gao MJ, Taylor G, Blackburn GM. Analogues of diadenosine 5′, 5′′′-P1, P4-tetraphosphate (Ap4A) as potential anti-platelet-aggregation agents. Proc Natl Acad Sci USA 1992; 89: 2370-3.
5. 12 and P2X1 receptors. Thromb Res 2010; 125: 159-65.
6. Chan SW, Gallo SJ, Kim BK, Guo MJ, Blackburn GM, Zamecnik PC. P1, P4-dithio-P2, P3-monochloromethylene diadenosine 5′, 5′′′-P1, P4-tetraphosphate: a novel antiplatelet agent. Proc Natl Acad Sci USA 1997; 94: 4034-9.
7. Mahaut-Smith MP, Tolhurst G, Evans RJ. Emerging roles for P2X1 receptors in platelet activation. Platelets 2004; 15: 131-44.
8. Westfall TD, McIntyre CA, Obeid S, Bowes J, Kennedy C, Sneddon P. The interaction of diadenosine polyphosphates with P2X-receptors in the guinea-pig isolated vas deferens. Br J Pharmacol 1997; 121: 57-62.
9. Lewis CJ, Gitterman DP, Schluter H, Evans RJ. Effects of diadenosine polyphosphates (Ap(n)As) and adenosine polyphospho guanosines (Ap(n)Gs) on rat mesenteric artery P2X receptor ion channels. Br J Pharmacol 2000; 129: 124-30.
10. Yanachkov IB, Dix EJ, Yanachkova MI, Wright GE. P1, P2-diimidazolyl derivatives of pyrophosphate and bis-phosphonates - synthesis, properties, and use in preparation of dinucleoside tetraphosphates and analogs. Org Biomol Chem 2011; 9: 730-8.
11. Han Q, Gaffney BL, Jones RA. One-flask synthesis of dinucleoside tetra- and pentaphosphates. Org Lett 2006; 8: 2075-7.
12. 12/thrombin in ADP- and thrombin-induced human platelet activation. Br J Pharmacol 2004; 142: 1325-31.
13. Turner NA, Moake JL, McIntire LV. Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow. Blood 2001; 98: 3340-5.
14. 12 antagonism: promises and challenges. Arterioscler Thromb Vasc Biol 2008; 28: s33-8.
15. 1-receptor. Mol Pharmacol 1996; 50: 1323-9.
16. 1 receptor antagonist. Br J Pharmacol 2002; 135: 2004-10.
17. 1 receptor ligands. J Med Chem 2000; 43: 829-42.
18. 1 receptor antagonists. Bioorg Med Chem 2004; 12: 1769-79.
19. Xu B, Stephens A, Kirschenheuter G, Greslin AF, Cheng X, Sennelo J, Cattaneo M, Zighetti ML, Chen A, Kim SA, Kim HS, Bischofberger N, Cook G, Jacobson KA. Acyclic analogues of adenosine bisphosphates as P2Y receptor antagonists: phosphate substitution leads to multiple pathways of inhibition of platelet aggregation. J Med Chem 2002; 45: 5694-709.
20. Raboisson P, Baurand A, Cazenave JP, Gachet CRM, Speiss B, Bourgignon JJ. Novel antagonists acting at the P2Y(1) purinergic receptor: synthesis and conformational analysis using potentiometric and nuclear magnetic resonance titration techniques. J Med Chem 2002; 45: 962-72.
21. 1 receptor: structure activity relationships and receptor docking. J Med Chem 2001; 44: 3092-108.
22. 1 receptor antagonists. J Med Chem 2003; 46: 4974-87.
23. 12 receptor. J Med Chem 2008; 51: 1007-25.
24. Kauffenstein G, Hechler B, Cazenave JP, Gachet C. Adenine triphosphate nucleotides are antagonists at the P2Y receptor. J Thromb Haemost 2004; 2: 1980-8.
25. Cattaneo M. ADP receptor antagonists. In: Michelson AD, ed. Platelets, 2nd edn. San Diego, CA: Elsevier/Academic Press, 2007: 1127-44.
26. 1 receptor. Mol Pharmacol 1998; 54: 1118-23.
27. Major DT, Nahum V, Wang Y, Reiser G, Fischer B. Molecular recognition in purinergic receptors. 2. Diastereoselectivity of the h-P2Y1-receptor. J Med Chem 2004; 47: 4405-16.
28. Hoyle CHV, Hilderman RH, Pintor JJ, Schlüter H, King BF. Diadenosine polyphosphates as extracellular signal molecules. Drug Dev Res 2001; 52: 260-73.
29. Delicado EG, Miras-Portugal MT, Carrasquero LM, Leon D, Perez-Sen R, Gualix J. Dinucleoside polyphosphates and their interaction with other nucleotide signaling pathways. Pflugers Arch 2006; 452: 563-72.
30. Pintor J, Diaz-Hernandez M, Gualix J, Gomez-Villafuertes R, Hernando F, Miras-Portugal MT. Diadenosine polyphosphate receptors. from rat and guinea-pig brain to human nervous system. Pharmacol Ther 2000; 87: 103-15.
31. Sage SO, MacKenzie AB, Jenner S, Mahaut-Smith MP. Purinoceptor-evoked calcium signalling in human platelets. Prostaglandins Leukot Essent Fatty Acids 1997; 57: 435-8.
32. Longhurst PA, Schwegel T, Folander K, Swanson R. The human P2X1 receptor: molecular cloning, tissue distribution, and localization to chromosome 17. Biochim Biophys Acta 1996; 1308: 185-8.
33. Jin J, Kunapuli SP. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci USA 1998; 95: 8070-4.
34. Cattaneo M, Gachet C. ADP receptors and clinical bleeding disorders. Arterioscler Thromb Vasc Biol 1999; 19: 2281-5.
35. Lin CY, Lubin B, Smith S. Inhibition of platelet aggregation by acyl-CoA thioesters. Biochim Biophys Acta 1976; 428: 45-55.
36. Manolopoulos P, Glenn JR, Fox SC, May JA, Dovlatova NL, Tang SW, Thomas NR, Ralevic V, Heptinstall S. Acyl derivatives of coenzyme A inhibit platelet function via antagonism at P2Y1 and P2Y12 receptors: a new finding that may influence the design of anti-thrombotic agents. Platelets 2008; 19: 134-45.
37. Tolhurst G, Vial C, Leon C, Gachet C, Evans RJ, Mahaut-Smith MP. Interplay between P2Y(1), P2Y(12), and P2X(1) receptors in the activation of megakaryocyte cation influx currents by ADP: evidence that the primary megakaryocyte represents a fully functional model of platelet P2 receptor signaling. Blood 2005; 106: 1644-51.
38. 12 receptors at the level of calcium signaling in human platelets. Blood 2004; 104: 1745-52.